Abstract: Sequences isolated from the 2 patients showed a high level of identity (>99%), both carrying the major IAS PI mutation M46I.
Drug resistant mutations detected by genotypic drug resistance testing in patients failing therapy in clade C HIV-1 infected individuals from India.
PMID: 19584504
2009
Indian journal of medical microbiology
Abstract: The M46I mutation was seen in 20% of the Pr sequences.
Failure of treatment with first-line lopinavir boosted with ritonavir can be explained by novel resistance pathways with protease mutation 76V.
PMID: 19627247
2009
The Journal of infectious diseases
Abstract: Addition of M46I, which did not confer any lopinavir resistance on its own, had a dual effect.
Abstract: CONCLUSIONS: The HIV protease substitution L76V, in combination with M46I, confers clinically relevant levels of lopinavir resistance and represents a novel resistance pathway to first-line lopinavir/r therapy.
Abstract: RESULTS: A detailed longitudinal analysis demonstrated the selection of the M46I+L76V protease mutations in all 3 patients.
Transmitted antiretroviral drug resistance among acute and recent HIV infections in North Carolina from 1998 to 2007.
Result: M46I, F53L, and G73S were each seen in only two samples each.
Minority variants associated with transmitted and acquired HIV-1 nonnucleoside reverse transcriptase inhibitor resistance: implications for the use of second-generation nonnucleoside reverse transcriptase inhibitors.
PMID: 19734799
2009
Journal of acquired immune deficiency syndromes (1999)
Result: The sample from PID 30062 - which contained four NRTI-resistance mutations - also had the following minority protease inhibitor (PI) resistance mutations: M46I (0.8%), I84V (0.9%), and L90M (0.9%) (data not shown).
Low prevalence of HIV type 1 drug resistance mutations in untreated, recently infected patients from Burkina Faso, Cote d'Ivoire, Senegal, Thailand, and Vietnam: the ANRS 12134 study.
PMID: 19886834
2009
AIDS research and human retroviruses
Abstract: Of the 266 RT and PR sequences analyzed, two from Vietnam harbored virus with major drug resistance mutations (G190A in RT for one individual and M46I in PR for the second individual).
Antiretroviral genotypic resistance mutations in HIV-1 infected Korean patients with virologic failure.
PMID: 19949656
2009
Journal of Korean medical science
Abstract: M184V/I mutation was observed in 36 patients (87.7%) followed by T215Y/F (41.5%) and M46I/L (34%).
Result: M184V/I mutation was observed in 36 patients (87.7%) followed by T215Y/F (17/41, 41.5%) and M46I/L (14/41, 34.2%).
Resampling-based analyses of the effects of combinations of HIV genetic mutations on drug susceptibility.
Abstract: Analysis of the data from the Stanford HIV database shows that while M46I/L mutations are associated with drug resistance, addition of the L88D/S mutation leads to hypersusceptible virus.
Characterization of a novel human immunodeficiency virus type 1 protease inhibitor, A-790742.
PMID: 18212102
2008
Antimicrobial agents and chemotherapy
Abstract: During in vitro selection, A-790742 selected two primary mutations (V82L and I84V) along with L23I, L33F, K45I, A71V/A, and V77I in the pNL4-3 background and two other mutations (A71V and V82G) accompanied by M46I and L63P in the HIV-1 RF background.
Multiple independent origins of a protease inhibitor resistance mutation in salvage therapy patients.
Introduction: Primary drug resistance mutations that alone confers moderate resistance such as V82A and L90M are initially selected followed by the addition of secondary mutations often located outside of the active site of the PR, such as L10I, M36I, M46I, L63P, or A71V leading to higher levels of resistance.
HIV mutation literature information.
PMID: 
2009
The new microbiologica
Browser Board
Co-occurred Entities
Filtrator
ViMRT